Development of a physiologically based pharmacokinetic model for chloroform.

No abstract is available for this paper.

• Publication year

  1990

• Venue

  Toxicology and Applied Pharmacology

• Publication date

  1990-05-01

• Fields of study

  Medicine, Chemistry, Environmental Science

• Identifiers
  DOI 10.1016/0041-008X(90)90324-NPMID 2339423
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Partition coefficients of low-molecular-weight volatile chemicals in various liquids and tissues.

  1989cited by this paper
• Incorporation of in vitro enzyme data into the physiologically-based pharmacokinetic (PB-PK) model for methylene chloride: implications for risk assessment.

  1988cited by this paper
• Physiologically based pharmacokinetic modeling with methylchloroform: implications for interspecies, high dose/low dose, and dose route extrapolations.

  1988cited by this paper
• Physiologically based pharmacokinetic model for vinylidene chloride.

  1988cited by this paper
• Physiologically based pharmacokinetics and the risk assessment process for methylene chloride.

  1987cited by this paper
• Chloroform hepatotoxicity in the Mongolian gerbil.

  1987cited by this paper
• A physiologically based simulation approach for determining metabolic constants from gas uptake data.

  1986cited by this paper
• Changes in cytochrome P450 molecular species in rat liver in chloroform intoxication.

  1986cited by this paper
• Biochemical alterations elicited in rat liver microsomes by oxidation and reduction products of chloroform metabolism.

  1986cited by this paper
• Bradycardia and hypoternion in spinal anaesthesia

  1986cited by this paper
• Carcinogenicity of Chloroform in Drinking Water to Male Osborne-Mendel Rats and Female B6C3F1 Mice

  1985cited by this paper
• Carcinogenicity of chloroform in drinking water to male Osborne-Mendel rats and female B6C3F1 mice.

  1985cited by this paper
• A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans.

  1984cited by this paper
• Effect of sex hormone status on chloroform nephrotoxicity and renal mixed function oxidases in mice.

  1984cited by this paper
• Mechanism of chloroform nephrotoxicity. III. Renal and hepatic microsomal metabolism of chloroform in mice.

  1984cited by this paper
• Effect of vehicle on the pharmacokinetics and uptake of four halogenated hydrocarbons from the gastrointestinal tract of the rat

  1983cited by this paper
• Distribution, excretion, and metabolism of 2,3,7,8-tetrachlorodibenzo-p-dioxin in C57BL/6J, DBA/2J, and B6D2F1/J mice.

  1983cited by this paper
• Mechanism of chloroform nephrotoxicity. I. Time course of chloroform toxicity in male and female mice.

  1983cited by this paper
• Mechanism of chloroform nephrotoxicity. II. In vitro evidence for renal metabolism of chloroform in mice.

  1983cited by this paper
• The pharmacokinetics and macromolecular interactions of trichloroethylene in mice and rats.

  1982cited by this paper
• Mechanistic considerations for carcinogenic risk estimation: chloroform.

  1982cited by this paper
• Structure and quantification of a physiological model of the distribution of injected agents and inhaled anaesthetics.

  1981cited by this paper
• The pharmacokinetics and macromolecular interactions of perchloroethylene in mice and rats as related to oncogenicity.

  1980cited by this paper
• Safety evaluation of toothpaste containing chloroform. I. Long-term studies in mice.

  1979cited by this paper
• Bioactivation of carbon tetrachloride, chloroform and bromotrichloromethane: role of cytochrome P-450.

  1977cited by this paper
• Phosgene: a metabolite of chloroform.

  1977cited by this paper
• The role of glutathione in chloroform-induced hepatotoxicity.

  1976cited by this paper
• Mechanisms of Acute Hepatic Toxicity: Chloroform, Halothane, and Glutathione

  1974cited by this paper
• Metabolism of Chloroform—I. The Metabolism of [14C] Chloroform by Different Species

  1974cited by this paper
• Acetaminophen-induced hepatic necrosis. VI. Metabolic disposition of toxic and nontoxic doses of acetaminophen.

  1974cited by this paper
• Solubility coefficients for inhaled anaesthetics for water, oil and biological media.

  1973cited by this paper
• Chloroform toxicity in mice: correlation of renal and hepatic necrosis with covalent binding of metabolites to tissue macromolecules.

  1973cited by this paper
• Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo.

  1973cited by this paper
• Pulmonary elimination of chloroform and its metabolite in man.

  1972cited by this paper
• Susceptibility of Male and Female Mice to the Nephrotoxic and Hepatotoxic Properties of Chlorinated Hydrocarbons.∗

  1967cited by this paper
• Tissue Weights of the Rat. I. Normal Values Determined By Dissection and Chemical Methods

  1956cited by this paper
• Induction of Hepatomas in Mice by Repeated Oral Administration of Chloroform, with Observations on Sex Differences

  1945cited by this paper

• Evaluation of hepatic and renal effects of acute and subacute oral exposure to bromochloromethane in rats.

  2025cites this paper
• Recommendations for the reference concentration of cadmium exposure based on a physiologically based toxicokinetic model integrated with a human respiratory tract model.

  2024cites this paper
• Pharmacokinetics of bromoform in dairy heifers

  2024cites this paper
• PBPK modeling to evaluate maximum tolerated doses: A case study with 3-chloroallyl alcohol

  2023cites this paper
• A Model Template Approach for Rapid Evaluation and Application of Physiologically Based Pharmacokinetic Models: Extension to Volatile Organic Compounds.

  2023cites this paper
• Physiologically Based Pharmacokinetic (PBPK) Modeling of RNAi Therapeutics: Opportunities and Challenges.

  2021cites this paper
• A holistic review on application of green solvents and replacement study for conventional solvents

  2021cites this paper
• A holistic review on application of green solvents and replacement study for conventional solvents

  2021cites this paper
• Global optimization of the Michaelis–Menten parameters using physiologically-based pharmacokinetic (PBPK) modeling and chloroform vapor uptake data in F344 rats

  2020influential citation
• Health risk assessment of trihalomethanes mixtures from daily water-related activities via multi-pathway exposure based on PBPK model.

  2018cites this paper
• Monte‐Carlo and multi‐exposure assessment for the derivation of criteria for disinfection byproducts and volatile organic compounds in drinking water: Allocation factors and liter‐equivalents per day

  2018cites this paper
• Enzyme Mediated Chloroform Biotransformation and Quantitative Cancer Risk Analysis of Trihalomethanes Exposure in South East Asia

  2017cites this paper
• Fuzzy Physiologically Based Pharmacokinetic (PBPK) Model of Chloroform in Swimming Pools

  2016cites this paper
• Health Effects Support Document for Perfluorooctane Sulfonate (PFOS)

  2016cites this paper
• Evaluation and modeling of the impact of coexposures to VOC mixtures on urinary biomarkers

  2016cites this paper
• Etudes et recherches

  2016cites this paper
• Biomarkers for the 21st century: listening to the microbiome.

  2015cites this paper
• Evaluation of simple in vitro to in vivo extrapolation approaches for environmental compounds.

  2014cites this paper
• Relative source allocation of TDI to drinking water for derivation of a criterion for chloroform: a Monte-Carlo and multi-exposure assessment.

  2013cites this paper
• Accounting for the impact of short-term variations in the levels of trihalomethane in drinking water on exposure assessment for epidemiological purposes. Part II: Biological aspects

  2013cites this paper
• Application of an updated physiologically based pharmacokinetic model for chloroform to evaluate CYP2E1-mediated renal toxicity in rats and mice.

  2013influential citation
• Physiologically based pharmacokinetic/toxicokinetic modeling.

  2012cites this paper
• Physiologically Based Pharmacokinetic (PBPK) Modeling of Metabolic Pathways of Bromochloromethane in Rats

  2012cites this paper
• Physiologically-based pharmacokinetic (PBPK) models in toxicity testing and risk assessment.

  2012cites this paper
• Interspecies extrapolation.

  2012cites this paper
• Approche multidisciplinaire pour l’amélioration de l’estimation de l’exposition aux sous-produits de désinfection de l’eau en milieu domestique et en piscine

  2012cites this paper
• In Silico Strategies for Modeling Stereoselective Metabolism of Pyrethroids

  2012cites this paper
• Evaluation of the impact of the exposure route on the human kinetic adjustment factor.

  2011cites this paper
• Challenges in the application of quantitative approaches in risk assessment: a case study with di-(2-ethylhexyl)phthalate

  2011cites this paper
• Biomonitoring of Pesticides: Pharmacokinetics of Organophosphorus and Carbamate Insecticides

  2011cites this paper
• Caractérisation de la composante toxicocinétique du facteur d’ajustement pour la variabilité interindividuelle utilisé en analyse du risque toxicologique

  2011cites this paper
• A non-invasive approach to study lifetime exposure and bioaccumulation of PCBs in protected marine mammals: PBPK modeling in harbor porpoises.

  2011cites this paper
• Modeling Exposure to Disinfection ByProducts

  2011cites this paper
• Development of a quantitative model incorporating key events in a hepatotoxic mode of action to predict tumor incidence.

  2010cites this paper
• Chloroform distribution and accumulation by combined inhalation plus oral exposure routes in rats

  2010cites this paper
• A Bayesian population PBPK model for multiroute chloroform exposure

  2010influential citation
• Chapter 66 – Organophosphorus Insecticide Pharmacokinetics

  2010cites this paper
• An Assessment of the Interindividual Variability of Internal Dosimetry during Multi-Route Exposure to Drinking Water Contaminants

  2010cites this paper
• Physiologically based modeling of p‐tert‐octylphenol kinetics following intravenous, oral or subcutaneous exposure in male and female Sprague–Dawley rats

  2010cites this paper
• Caractérisation de la toxicocinétique de l’octylphénol chez le rat en vue d’une meilleure analyse de risque toxicologique des perturbateurs endocriniens

  2009cites this paper
• Acute Exposure Guideline Levels for Selected Airborne Chemicals: Volume 15

  2009cites this paper
• A physiologic pharmacokinetic model for styrene and styrene-7,8-oxide in mouse, rat and man

  2009cites this paper
• Physiologically Based Pharmacokinetic Modelling

  2009cites this paper
• Mode of Action Frameworks in Toxicity Testing and Chemical Risk Assessment

  2009cites this paper
• The Influence of Genetic Polymorphisms on Population Variability in Six Xenobiotic-Metabolizing Enzymes

  2009cites this paper
• Mode of action considerations in the quantitative assessment of tumour responses in the liver.

  2009cites this paper
• Development and Application of Biomonitoring Equivalents for Interpreting Biomonitoring Data in a Human Health Risk Context

  2009cites this paper
• Effect of PBPK model structure on interpretation of in vivo human aqueous dermal exposure trials.

  2008cites this paper
• In vitro measurements of metabolism for application in pharmacokinetic modeling.

  2008cites this paper
• Development and specification of physiologically based pharmacokinetic models for use in risk assessment.

  2008cites this paper
• Disinfection by-products and public health concerns

  2008cites this paper
• Time dependencies in perfluorooctylacids disposition in rat and monkeys: a kinetic analysis.

  2008cites this paper
• Biomonitoring Equivalents (BE) dossier for trihalomethanes.

  2008influential citation
• Reverse dosimetry: interpreting trihalomethanes biomonitoring data using physiologically based pharmacokinetic modeling

  2007influential citation
• Bayesian Estimation of Pharmacokinetic and Pharmacodynamic Parameters in a Mode‐of‐Action‐Based Cancer Risk Assessment for Chloroform

  2007influential citation
• A physiologically based pharmacokinetic/pharmacodynamic model for carbofuran in Sprague-Dawley rats using the exposure-related dose estimating model.

  2007influential citation
• Methods and Measurements for Estimating Human Dermal Uptake of Volatile Organic Compounds and for Deriving Dermal Permeability Coefficients

  2007cites this paper
• STUDY OF SOME HEALTH EFFECTS IN WORKERS EXPOSED TO CHLOROFORM

  2007cites this paper
• Pharmacokinetic modeling of saturable, renal resorption of perfluoroalkylacids in monkeys--probing the determinants of long plasma half-lives.

  2006cites this paper
• Toxicokinetics: Fundamentals and Applications in Drug Development and Safety Assessment

  2006cites this paper
• Use of a Physiologically Based Pharmacokinetic Model to Identify Exposures Consistent With Human Biomonitoring Data for Chloroform

  2006cites this paper
• Chemical Risk Assessment

  2006cites this paper
• Development of Physiologically Based Toxicokinetic Models for Improving the Human Indoor Exposure Assessment to Water Contaminants: Trichloroethylene and Trihalomethanes

  2006cites this paper
• Physiologically Based Pharmacokinetic Modeling of Organophosphorus and Carbamate Pesticides

  2006cites this paper
• Pharmacokinetic/Physiologically Based Pharmacokinetic Models in Integrated Risk Information System Assessments

  2006cites this paper
• Determination of age and gender differences in biochemical processes affecting the disposition of 2-butoxyethanol and its metabolites in mice and rats to improve PBPK modeling.

  2005cites this paper
• Human respiratory uptake of chloroform and haloketones during showering

  2005cites this paper
• Characterization of the Metabolic Interaction between Trihalomethanes and Chloroacetic Acids using Rat Liver Microsomes

  2005influential citation
• Improving Predictive Modeling in Pediatric Drug Development: Pharmacokinetics, Pharmacodynamics, and Mechanistic Modeling

  2005cites this paper
• Risk assessment of chemicals and pharmaceuticals in the pediatric population: a workshop report.

  2005cites this paper
• In vitro kinetics of styrene and styrene oxide metabolism in rat, mouse, and human

  2005cites this paper
• Physiologically Based Pharmacokinetic Modeling

  2004cites this paper
• PRINCIPLES OF CHARACTERIZING AND APPLYING HUMAN EXPOSURE MODELS

  2004cites this paper
• The Metabolic Rate Constants and Specific Activity of Human and Rat Hepatic Cytochrome P-450 2E1 Toward Toluene and Chloroform

  2004influential citation
• Analysis of in vivo and in vitro DNA strand breaks from trihalomethane exposure

  2004cites this paper
• Visualization-Based Analysis for a Mixed-Inhibition Binary PBPK Model: Determination of Inhibition Mechanism

  2004cites this paper
• Assessing the dose-dependency of allometric scaling performance using physiologically based pharmacokinetic modeling.

  2003cites this paper
• Biologically motivated computational modeling of chloroform cytolethality and regenerative cellular proliferation.

  2003influential citation
• A Framework for Human Relevance Analysis of Information on Carcinogenic Modes of Action

  2003cites this paper
• Physiologically based pharmacokinetic model parameter estimation and sensitivity and variability analyses for acrylonitrile disposition in humans.

  2003cites this paper
• Acute and Subchronic Inhalation Toxicity of Chloroform in Rats and Mice

  2002cites this paper
• Chloroform inhalation exposure conditions necessary to initiate liver toxicity in female B6C3F1 mice.

  2002cites this paper
• CANCER RISK ASSOCIATED WITH HOUSEHOLD EXPOSURE TO CHLOROFORM

  2002cites this paper
• A comparison of Haber's rule at different ages using a physiologically based pharmacokinetic (PBPK) model for chloroform in rats.

  2002cites this paper
• COMPARING RESPIRATORY-TRACT AND HEPATIC EXPOSURE-DOSE RELATIONSHIPS FOR METABOLIZED INHALED VAPORS: A PHARMACOKINETIC ANALYSIS

  2002influential citation
• Chloroform 21 3 Toxicokinetics and Metabolism 3 . 1

  2002cites this paper
• CHLOROFORM: EXPOSURE ESTIMATION, HAZARD CHARACTERIZATION, AND EXPOSURE-RESPONSE ANALYSIS

  2002influential citation
• Classification of carcinogenic chemicals in the work area by the German MAK Commission: current examples for the new categories.

  2001cites this paper
• Parents worried about breast milk contamination. What is best for baby?

  2001cites this paper
• An innovative method to determine percutaneous absorption: Real-time breath analysis and physiologically based pharmacokinetic modeling

  2001cites this paper
• Development of a preliminary physiologically based toxicokinetic (PBTK) model for 1,3-butadiene risk assessment.

  2001cites this paper
• Correlation of a specific mitochondrial phospholipid-phosgene adduct with chloroform acute toxicity.

  2001cites this paper
• CHAPTER 46 – Organophosphate Pharmacokinetics

  2001cites this paper
• A Graphical Application of Sensitivity Analysis for Gas Uptake Experiments Using Chloroform as an Example

  2001cites this paper
• HUMAN EXPOSURE TO VOLATILE ORGANIC POLLUTANTS: Implications for Indoor Air Studies ⁄

  2001cites this paper
• Development of a physiologically based pharmacokinetic model for hydroquinone.

  2000cites this paper
• The utility of PBPK in the safety assessment of chloroform and carbon tetrachloride.

  2000cites this paper
• Comparing Occupational and Environmental Risk Assessment Methodologies Using Pharmacokinetic Modeling

  2000cites this paper
• Organohalogenated compounds levels in chlorinated drinking waters and current compliance with quality standards throughout the European Union

  2000cites this paper
• Physiologically based pharmacokinetic modeling of the temperature-dependent dermal absorption of chloroform by humans following bath water exposures.

  2000cites this paper